OKYO (OKYO Pharma) Scaled Net Operating Assets: -2.03 (As of Sep. 2025)


OKYO OKYO Pharma Ltd OKYO
23 GF Score
Price $1.75
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma Scaled Net Operating Assets?

OKYO Pharma OKYO +8.70% 23 Scaled Net Operating Assets is -2.03 as of Sep. 2025. GuruFocus rates OKYO with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

OKYO Pharma's operating assets for the quarter that ended in Sep. 2025 was $0.42 Mil. OKYO Pharma's operating liabilities for the quarter that ended in Sep. 2025 was $7.87 Mil. OKYO Pharma's Total Assets for the quarter that ended in Mar. 2025 was $3.68 Mil. Therefore, OKYO Pharma's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2025 was -2.03.

OKYO Pharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Scaled Net Operating Assets Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.46 0.04 -0.90 -1.29 -4.62

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -5.33 -2.51 -2.03

OKYO vs ENTX, HRTX, RANI: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, OKYO Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Scaled Net Operating Assets falls into.


OKYO
23GF Score
OKYO Pharma Ltd OKYO
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

OKYO Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2025 )
=(Operating Assets (A: Mar. 2025 )-Operating Liabilities (A: Mar. 2025 ))/Total Assets (A: Mar. 2024 )
=(2.116-9.227)/1.541
=-4.61

where

Operating Assets(A: Mar. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.677 - 1.561
=2.116

Operating Liabilities(A: Mar. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=9.227 - 0 - 0
=9.227

OKYO Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2025 )
=(Operating Assets (Q: Sep. 2025 )-Operating Liabilities (Q: Sep. 2025 ))/Total Assets (Q: Mar. 2025 )
=(0.424-7.873)/3.677
=-2.03

where

Operating Assets(Q: Sep. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4.644 - 4.22
=0.424

Operating Liabilities(Q: Sep. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.059 - 0 - 0.186
=7.873

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -2.03 mean?
OKYO Pharma (OKYO) has a Scaled Net Operating Assets of -2.03 as of Sep. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on OKYO Pharma and its competitors.
Is OKYO Pharma's Scaled Net Operating Assets too high?
OKYO Pharma's current Scaled Net Operating Assets is -2.03. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Scaled Net Operating Assets compare to ENTX and HRTX?
OKYO Pharma's Scaled Net Operating Assets of -2.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current Scaled Net Operating Assets is -2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (OKYO) has a current Scaled Net Operating Assets of -2.03. The current Scaled Net Operating Assets is -2.03. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For OKYO Pharma (OKYO), the current Scaled Net Operating Assets is -2.03 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for OKYO

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price